Olympus Scope Leads
Represent patients who contracted CRE, sepsis, or other serious infections after undergoing a procedure involving an Olympus duodenoscope, cystoscope, ureteroscope, choledochoscope, or hysteroscope.
Olympus Duodenoscope & Endoscope Infection Litigation
Olympus Corp. — the manufacturer of roughly 85% of the U.S. duodenoscope market — has been tied to more than 400 confirmed superbug infections across 36+ hospitals and at least 35 deaths documented by the U.S. Senate HELP Committee. Internal communications show Olympus knew its TJF-Q180V duodenoscope design trapped bacteria as early as 2012, but concealed warnings from U.S. regulators until 2015. In January 2025, Olympus recalled the MAJ-891 endoscope tubing set after 120 reported injuries and one death. The FDA issued an import alert on 58 Olympus products in June 2025, and an Urgent Field Safety Notice followed in October 2025 citing two additional deaths and five injuries. In 2018, Olympus paid an $85 million criminal fine for failing to report device-related injuries. Case values include the landmark Bigler verdict of $6.6 million plus $250,000 in concealment sanctions. Litigation is now expanding beyond duodenoscopes to cystoscopes, ureteroscopes, choledochoscopes, and hysteroscopes.
Associated Conditions
- CRE (Carbapenem-Resistant Enterobacteriaceae) infection
- Sepsis or septic shock requiring ICU admission
- Bacteremia or bloodstream infection
- E. coli, Klebsiella, or Pseudomonas infection
- Cholangitis or post-ERCP infection
- Urinary tract infection after cystoscopy or ureteroscopy
- Wrongful death following an Olympus scope procedure
Claimant Eligibility
- Underwent a procedure using an Olympus duodenoscope, cystoscope, ureteroscope, choledochoscope, or hysteroscope (including TJF-Q180V, TJF-160F, and MAJ-891 tubing)
- Diagnosed with a bacterial infection, sepsis, or CRE within 30 days of the scope procedure
- Hospitalization, ICU admission, or extended medical treatment required as a result of the infection
- Procedure occurred at a U.S. hospital or ambulatory surgical center from 2012 onward
- Wrongful death claims accepted where the decedent died from post-procedure infection complications
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Ready to review your next mass tort campaign?
Tell us about your firm, target cases, and intake capacity. A strategist will respond within one business day with practical next steps.
Built for personal injury firms, intake teams, and mass tort dockets